MARKET

CAMP

CAMP

Camp4 Therapeutics Corp.
NASDAQ
6.00
-0.13
-2.12%
After Hours: 6.22 +0.22 +3.67% 19:15 01/02 EST
OPEN
6.22
PREV CLOSE
6.13
HIGH
6.22
LOW
5.96
VOLUME
107.74K
TURNOVER
--
52 WEEK HIGH
7.31
52 WEEK LOW
1.305
MARKET CAP
311.29M
P/E (TTM)
-2.4236
1D
5D
1M
3M
1Y
5Y
1D
Getty Images, Torm, and More Stocks See Action From Activist Investors
Barron‘s · 1d ago
Weekly Report: what happened at CAMP last week (1222-1226)?
Weekly Report · 12/29/2025 09:21
CAMP4 Therapeutics Restructures Leases and Expands Facilities
TipRanks · 12/23/2025 22:18
Camp4 Therapeutics Amends Cambridge Lease and Accelerates Termination Date
Reuters · 12/23/2025 22:00
Weekly Report: what happened at CAMP last week (1215-1219)?
Weekly Report · 12/22/2025 09:21
GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst
Benzinga · 12/19/2025 15:36
CAMP4 Therapeutics: GSK Collaboration and Strengthened Funding Base De-Risk CMP-002 Development and Support Buy Rating
TipRanks · 12/19/2025 11:25
CAMP4 Therapeutics Announces $28 Million Common Stock Offering
TipRanks · 12/18/2025 22:53
More
About CAMP
CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. It is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.

Webull offers Camp4 Therapeutics Corp. stock information, including NASDAQ: CAMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CAMP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CAMP stock methods without spending real money on the virtual paper trading platform.